1. Disis, M.L., J.R. Gralow, H. Bernhard, S.L. Hand, W.D. Rubin, and M.A. Cheever. 1996. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156:3151–3158.
2. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336–1343.
3. Berzofsky, J.A., L.J. Helman, and D.P. Carbone. 2000. Oncogene products and mutated proteins as tumor antigens. In Biologic Therapy of Cancer: Principles and Practice (3rd Ed.). S.A. Rosenberg, ed. Lippincott Williams & Wilkins, Philadelphia: 526–541.
4. Berzofsky, J.A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann N Y Acad Sci 690:256–264.
5. Berzofsky, J.A., J.D. Ahlers, M.A. Derby, C.D. Pendleton, T. Arichi, and I.M. Belyakov. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol Rev 170:151–172.